Project Grant RF1AG077570
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $619,099 Project Grant to the University of California, Irvine under the Aging Research program (CFDA 93.866) effective February 1, 2026 through January 31, 2031. This five-year research initiative addresses a critical knowledge gap by investigating longitudinal relationships between Alzheimer's Disease (AD) pathophysiology, local sleep expression, and sleep-dependent memory across preclinical disease stages. The...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $450,000 in funding to Old Dominion University to investigate the relationship between disturbed sleep and the development of vulnerable atherosclerotic plaques. The primary objectives are to: 1) examine the role of NADPH-dependent oxidative stress in accelerating the formation of vulnerable atherosclerotic plaques in...
- This Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research into the molecular interplay of sleep and neurodegeneration using the Drosophila model system. With $2.14 million provided over 11 months, the Trustees of the University of Pennsylvania will investigate how expression of the TDP-43 protein linked to neurodegenerative diseases disrupts sleep in fruit flies. Researchers will aim to define the specific glial subtypes...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received $691,009 in project grant funding from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded March 15, 2026, with a completion date of February 28, 2031. This research project investigates the proteomic signature of sleep and its implications for Alzheimer's disease by examining the relationship between sleep architecture, circulating protein biomarkers, and...
- This federal Project Grant award, totaling $2,683,965.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the establishment of a human microphysiological system to elucidate cellular mechanisms underlying vulnerability to Alzheimer's disease (AD). The grant recipient, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare...
- Federal Project Grant Award Summary The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai a $464,750 Project Grant effective September 5, 2025, through August 31, 2027, under the Aging Research program (CFDA 93.866). This award funds a research initiative investigating the distinct contributions of chronic sleep disruption and intermittent hypoxia in obstructive sleep apnea (OSA) to tau pathology and propagation in the brain. The research aims to establish causal...
- This $7.72 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The Seattle Institute for Biomedical and Clinical Research will define the role of post-traumatic brain injury sleep disruption and glymphatic dysfunction in the development of Alzheimer's disease and chronic traumatic encephalopathy neuropathology. Over three years, the grantee and three sub-awardees will...
- SUMMARY New York University School of Medicine was awarded $642,063 by the National Institute on Aging under the Aging Research program (CFDA 93.866) on January 15, 2026, for a project grant extending through December 31, 2030. The award supports scientific research investigating gabaergic circuit targets within the hippocampal CA1 region as potential therapeutic mechanisms for modulating entorhinal cortex-hippocampus dynamics in Alzheimer's disease patients. The research project will deliver...
- Federal Project Grant Award Summary The Washington University, through its Office of Sponsored Research Services, received a $125,000 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded on September 15, 2025, with a completion date of June 30, 2027. The award funds research investigating epigenetic modulations by sleep to mitigate neurodegeneration, specifically examining the mechanistic relationship between sleep loss and tau protein aggregation in...
- Federal Grant Award Summary The National Institute on Aging awarded Massachusetts General Hospital (MGH) $868,901 under the Aging Research program (CFDA 93.866) on March 1, 2026, for the SLEEP-POD2 project (Sleep and Circadian Rhythm Biomarkers of Postoperative Neurocognitive Recovery). This longitudinal research initiative will conduct a comprehensive investigation into the relationship between perioperative sleep disruption, circadian rhythm disturbances, and postoperative delirium (POD) in...
SLEEP, PERICYTES, AND ALZHEIMER'S DISEASE - ABSTRACT THIS PROPOSAL RESPONDS TO THE NIH HIGH-PRIORITY RESEARCH TOPICS ANNOUNCEMENTS FOR PAR-19-070: MECHANISM UNDERLYING THE VASCULAR RISK, SLEEP EFFICIENCY, AND CHRONIC CIRCADIAN DISRUPTION IN THE ETIOLOGY OF ALZHEIMER'S DISEASE (AD). WE ARE A RESEARCH GROUP FOCUSING ON THE BRAIN CIRCUITRY OF SLEEP DISORDER NARCOLEPSY (CAUSED BY LOSS OF THE HYPOTHALAMIC WAKE-PROMOTING OREXIN NEURONS). BY FOLLOWING THE EMERGING SCIENTIFIC EVIDENCE ON THE PROTECTIVE EFFECTS OF SLEEP FOR AD, WE PROPOSE INVESTIGATING THE INTRINSIC MECHANISM INVOLVED. PERICYTES, A TYPE OF MURAL CELLS OF THE CAPILLARY AND A KEY COMPONENT OF THE NEUROVASCULAR UNIT (NVU), BECOME OUR FOCUS BECAUSE OF THEIR UNIQUE FUNCTION IN REGULATING CEREBRAL BLOOD FLOW (CBF) AND THE BLOOD-BRAIN BARRIER (BBB) PERMEABILITY. STRONG EVIDENCE SUGGESTS THAT PERICYTES MALFUNCTION OR DEGENERATION CONTRIBUTES TO AD PATHOLOGY BY AFFECTING CBF AND BREAKING DOWN BBB. INTRIGUINGLY, SIMILAR MECHANISMS ALSO UNDERLIE THE CONTRIBUTION OF SLEEP LOSS TO AD PATHOLOGY. THUS, WE ASK WHETHER PERICYTES ARE THE MEDIATOR BETWEEN SLEEP AND AD PATHOLOGY. IMPROVING SLEEP MIGHT DELAY AD PATHOGENESIS BY PROTECTING PERICYTES AND MAINTAINING BBB INTEGRITY. IT IS THE FIRST TIME THAT BRAIN PERICYTES ARE STUDIED IN THE FRAMEWORK OF SLEEP AND AD. RECENT ADVANCES IN PERICYTE RESEARCH AND OUR LATEST PRELIMINARY DATA SHOW THE FEASIBILITY OF THE APPROACH. THIS PROJECT WILL HAVE CONFIRMED THE FUNCTIONAL CORRELATIONS AMONG PERICYTES, SLEEP, AND AD PATHOGENESIS AT THE END OF THE FUNDING PERIOD AND PROVIDED VALUABLE EVIDENCE FOR FUTURE PERICYTES-BASED THERAPIES FOR AD AND SLEEP DISORDERS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/25/25 | ||
| Not listed | $2.0m | 5/12/22 |